Biolife secures AU patent for cancer vaccine
Biolife Science has been granted an Australian patent covering cancer vaccine candidate HER-Vaxx.
The patent covers HER-Vaxx’s action against cancers associated with tumour antigen protein HER-2/neu. It grants Biolife Science intellectual property protection through to 2027.
HER-Vaxx is designed to stimulate HER-2 antibodies in early-stage cancer patients and has the potential to be a more potent alternative to Roche’s injectable antibody Herceptin. Nearly 20% of stomach cancers and 25-30% of breast cancers are HER-2 positive.
“With our intellectual property for HER-Vaxx now secured, we will have added confidence in its commercial viability moving forward,” Biolife Chariman-elect Dr Roger Aston said.
Biolife is currently conducting a backdoor ASX listing through a reverse takeover with ASX shell company Acuvax and an associated placement.
The company aims to raise up to $5 million through the placement to help fund phase II clinical trials for HER-Vaxx. Dr Aston and Paul Hooper have been selected to help lead the combined company.
“Biolife is eager to finalise its listing on the ASX and proceed with clinical trials of HER-Vaxx to further prove its effectiveness,” Dr Aston said.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
